share_log

Redhill Biopharma | UPLOAD: Others

Redhill Biopharma | UPLOAD: Others

Redhill Biopharma | UPLOAD:其他
SEC announcement ·  02/14 12:59
Moomoo AI 已提取核心信息
RedHill Biopharma Ltd., a biopharmaceutical company, received a notification from the United States Securities and Exchange Commission (SEC) on February 14, 2024, regarding its Registration Statement on Form F-1, which was filed on February 9, 2024. The SEC informed the company that it has not reviewed and will not review the registration statement. The SEC's communication reminded RedHill Biopharma of its responsibility for the accuracy and adequacy of the disclosures in the registration statement. The SEC also pointed out Rules 460 and 461, which pertain to requests for acceleration of the registration process. RedHill Biopharma's CEO, Dror Ben-Asher, was directed to contact Tim Buchmiller at the SEC with any further questions.
RedHill Biopharma Ltd., a biopharmaceutical company, received a notification from the United States Securities and Exchange Commission (SEC) on February 14, 2024, regarding its Registration Statement on Form F-1, which was filed on February 9, 2024. The SEC informed the company that it has not reviewed and will not review the registration statement. The SEC's communication reminded RedHill Biopharma of its responsibility for the accuracy and adequacy of the disclosures in the registration statement. The SEC also pointed out Rules 460 and 461, which pertain to requests for acceleration of the registration process. RedHill Biopharma's CEO, Dror Ben-Asher, was directed to contact Tim Buchmiller at the SEC with any further questions.
生物制药公司RedHill Biopharma Ltd. 于2024年2月14日收到美国证券交易委员会(SEC)关于其于2024年2月9日提交的F-1表格注册声明的通知。美国证券交易委员会告知该公司,它尚未审查注册声明,也不会审查注册声明。美国证券交易委员会的来文提醒RedHill Biopharma,它对注册声明中披露的准确性和充分性负责。美国证券交易委员会还指出了与加快注册程序的请求有关的第460和461条。如果有任何其他问题,红山生物制药首席执行官德罗尔·本·阿舍尔被指示联系美国证券交易委员会的蒂姆·布赫米勒。
生物制药公司RedHill Biopharma Ltd. 于2024年2月14日收到美国证券交易委员会(SEC)关于其于2024年2月9日提交的F-1表格注册声明的通知。美国证券交易委员会告知该公司,它尚未审查注册声明,也不会审查注册声明。美国证券交易委员会的来文提醒RedHill Biopharma,它对注册声明中披露的准确性和充分性负责。美国证券交易委员会还指出了与加快注册程序的请求有关的第460和461条。如果有任何其他问题,红山生物制药首席执行官德罗尔·本·阿舍尔被指示联系美国证券交易委员会的蒂姆·布赫米勒。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息